research Preparation of3H-labelled testosterone metabolites
The conclusion is that tritium-labeled testosterone metabolites can be made and are better converted into dihydrotestosterone in skin cells than in prostate tissue.
Search
for
Sort by
Research
180-210 / 1000+ results research The role of 5-alpha-reductase inhibitors in active surveillance
5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.
research 1424 METHYLATION AND DECREASED EXPRESSION OF 5-ALPHA REDUCTASE 2 IN HUMAN PROSATE SAMPLES: IMPLICATIONS FOR RESISTANCE TO THERAPY FOR BPH
Methylation of the 5-AR2 gene may cause resistance to Finasteride in BPH patients.
research L'etude PCPT : regards d'un urologue intéressé
Finasteride may reduce prostate cancer risk.
research Economic Issues in the Treatment of BPH
Combination therapy for BPH is cost-effective, especially for men with larger prostates.
research Redefining hormone resistance in prostate cancer
The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
research 342 COMPARISON OF THE INCIDENCE OF SECONDARY CANCERS AFTER IMRT, BRACHYTHERAPY AND SURGERY FOR THE TREATMENT OF PROSTATE CANCER
Different prostate cancer treatments have similar risks of secondary cancers and related mortality when considering patient age and smoking history.
research SHPro ® (mixture of Angelica gigas and Astragalus membranaceus ) in men with lower urinary tract symptoms: A randomized, double-blind, placebo-controlled clinical trial
SHPro® improved urinary symptoms and erectile function in men and is safe.
research Medical Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
Treatment for benign prostatic hyperplasia involves drugs that either quickly relieve symptoms or reduce prostate size, with a combination offering more benefits but more side effects.
research Biomarker-based methods for determining noncompliance in a prevention trial
Simple methods using DHT levels effectively assess compliance.
research Trimodal Mini‐Invasive Therapy for Stable‐Phase Peyronie's Disease: A Two‐Center Real‐Life Prospective Pilot Study
PRP injections are safe but don't significantly improve Peyronie's Disease.
research The research of Finasteride and Tamsulosin to reduce hemorrhage during TURP
Taking finasteride for over a month before surgery reduces blood loss during TURP.
research The effective course of finasteride pretreatment in decreasing blood loss associated with TURP
Taking finasteride for at least 3 months before TURP reduces blood loss.
research 토마토 추출액 복합체가 전립선 암 세포와 전립선 비대증에 미치는 영향
PLX, a tomato extract mix, may help treat prostate issues like BPH.
research PD16-01 NEW INSIGHT OF PSA REDUCTION DURING FINASTERIDE THERAPY
Finasteride reduces PSA levels by around 40-50% in BPH patients.
research Safety and efficacy of advanced and targeted acid α-glucosidase (AT-GAA) (ATB200/AT2221) in ERT-switch nonambulatory patients with Pompe disease: preliminary results from the ATB200-02 trial
The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
research Association between prostate‐specific antigen and serum testosterone: A systematic review and meta‐analysis
Testosterone replacement therapy, especially intramuscular, raises PSA levels, but no overall link between PSA and testosterone was found except in non-BPH patients.
research Saw palmetto and finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome
research 1262 ONE YEAR FINASTERIDE THERAPY IN MEN WITH A SERUM PSA GREATER THAN 4 NG/ML WHO HAD UNDERGONE REPEAT BIOPSY
Finasteride therapy reduces PSA levels and prostate size, helping diagnose prostate cancer.
research Acute urinary retention: risks and management.
Older men with severe symptoms and larger prostates should focus on prevention, using finasteride and alpha-blockers to manage acute urinary retention.
research 5‐α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population‐based cohort study
5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.
research An isotope dilution-liquid chromatography-tandem mass spectrometry-based candidate reference measurement procedure for the quantification of 5-alpha-dihydrotestosterone in human serum and plasma
The procedure accurately measures 5-alpha-dihydrotestosterone in blood, useful for standard tests.
research IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study
IsoPSA test works accurately even if patients take certain prostate medications.
research Trimodal mini-invasive therapy for stable-phase Peyronie's disease: a two-center real-life prospective pilot study
PRP injections with tadalafil and stretching safely improved Peyronie's symptoms but didn't significantly change curvature long-term.
research Slow progress in prostate cancer
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
research 5ARI and PSA: open questions
5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.
research UP-03.20
Combination therapy with Finasteride is more effective than alpha-blocker alone for BPH symptoms in small prostate volume.
research Medikamentöse Therapie der BPH Ist eine Kombinationstherapie mit 5α-Reduktasehemmern und α-Rezeptorenblockern sinnvoll?
Combination therapy is more effective for prostate volumes over 60 ml.
research UP-02.010 Urinary PSA: Marker of Benign Prostatic Hyperplasia?
Urinary PSA could be an early marker for enlarged prostate.
research Финастерид в профилактике прогрессирования рака предстательной железы
Finasteride reduces prostate size, improves urination, and slows prostate cancer progression.